JP2019516737A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516737A5
JP2019516737A5 JP2018560884A JP2018560884A JP2019516737A5 JP 2019516737 A5 JP2019516737 A5 JP 2019516737A5 JP 2018560884 A JP2018560884 A JP 2018560884A JP 2018560884 A JP2018560884 A JP 2018560884A JP 2019516737 A5 JP2019516737 A5 JP 2019516737A5
Authority
JP
Japan
Prior art keywords
methyl
amino
benzenesulfonamide
thiazol
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516737A (ja
JP6938545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033634 external-priority patent/WO2017201468A1/en
Publication of JP2019516737A publication Critical patent/JP2019516737A/ja
Publication of JP2019516737A5 publication Critical patent/JP2019516737A5/ja
Priority to JP2021142186A priority Critical patent/JP2021185189A/ja
Application granted granted Critical
Publication of JP6938545B2 publication Critical patent/JP6938545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560884A 2016-05-20 2017-05-19 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 Active JP6938545B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142186A JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662339773P 2016-05-20 2016-05-20
US62/339,773 2016-05-20
US201662432152P 2016-12-09 2016-12-09
US62/432,152 2016-12-09
PCT/US2017/033634 WO2017201468A1 (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142186A Division JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2019516737A JP2019516737A (ja) 2019-06-20
JP2019516737A5 true JP2019516737A5 (enExample) 2020-06-25
JP6938545B2 JP6938545B2 (ja) 2021-09-22

Family

ID=58794232

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018560884A Active JP6938545B2 (ja) 2016-05-20 2017-05-19 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2021142186A Withdrawn JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2023099277A Withdrawn JP2023108032A (ja) 2016-05-20 2023-06-16 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2025068729A Pending JP2025105687A (ja) 2016-05-20 2025-04-18 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021142186A Withdrawn JP2021185189A (ja) 2016-05-20 2021-09-01 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2023099277A Withdrawn JP2023108032A (ja) 2016-05-20 2023-06-16 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
JP2025068729A Pending JP2025105687A (ja) 2016-05-20 2025-04-18 ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用

Country Status (23)

Country Link
US (4) US10246453B2 (enExample)
EP (1) EP3458449B1 (enExample)
JP (4) JP6938545B2 (enExample)
KR (1) KR102366077B1 (enExample)
CN (1) CN109526219B (enExample)
AU (2) AU2017268006B2 (enExample)
CA (1) CA3023465C (enExample)
CL (1) CL2018003260A1 (enExample)
CO (1) CO2018012485A2 (enExample)
ES (1) ES3022639T3 (enExample)
HR (1) HRP20250505T1 (enExample)
HU (1) HUE071358T2 (enExample)
IL (1) IL262834B (enExample)
MX (1) MX386471B (enExample)
MY (1) MY199208A (enExample)
PH (1) PH12018502378B1 (enExample)
PL (1) PL3458449T3 (enExample)
RS (1) RS66796B1 (enExample)
RU (1) RU2769827C2 (enExample)
SG (2) SG11201809702SA (enExample)
TN (1) TN2018000385A1 (enExample)
WO (1) WO2017201468A1 (enExample)
ZA (1) ZA201807518B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458449B1 (en) 2016-05-20 2025-03-05 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
AU2017371674B2 (en) 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
UA127024C2 (uk) * 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN119118894A (zh) * 2019-11-21 2024-12-13 犹他大学研究基金会 Trpv4受体配体
WO2022077094A1 (en) * 2020-10-13 2022-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels
EP4228654A4 (en) * 2020-10-13 2024-10-16 Xenon Pharmaceuticals Inc. USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER, (S)-4-((1-BENZYLPYRROLIDIN-3-YL))(METHYL) AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL) BENZENESULFONAMIDE, IN CONJUNCTION WITH STRONG CYTOCHROME P450 3A4 INDUCERS, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAV1.6 ACTIVITY
WO2023235734A1 (en) 2022-06-02 2023-12-07 Neurocrine Biosciences, Inc. Deuterated compounds
AU2024296422A1 (en) * 2023-07-07 2025-12-18 Novartis Ag Sodium channel blockers
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
WO2025132758A1 (en) 2023-12-21 2025-06-26 Syngenta Crop Protection Ag Pesticidally active quinazoline compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
ES2187024T3 (es) 1997-05-07 2003-05-16 Galen Chemicals Ltd Dispositivo intravaginales de liberacion de farmacos para la adimistracion testosterona y de precursores de testosterona.
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
EP1202724B1 (en) 1999-07-16 2003-10-01 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005005421A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
JP2007501804A (ja) 2003-08-08 2007-02-01 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
JP2008524244A (ja) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
KR20080053931A (ko) 2005-10-06 2008-06-16 사노피-아벤티스 4-옥시-n-[1,3,4]-티아디아졸-2-일-벤젠 설폰아미드, 이의제조방법 및 약제로서의 이의 용도
CA2633653A1 (en) * 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
AU2007286344A1 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
EP2078018B1 (en) 2006-10-19 2012-03-14 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
JP5463285B2 (ja) 2007-07-13 2014-04-09 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
MY157017A (en) 2009-01-12 2016-04-15 Pfizer Ltd Sulfonamide derivatives
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
RU2563644C2 (ru) 2010-08-20 2015-09-20 Хатчисон Медифарма Лимитед Пирролопиримидиновые соединения и их применения
JP2014521749A (ja) 2011-08-17 2014-08-28 アムジエン・インコーポレーテツド ヘテロアリールナトリウムチャネル阻害剤
CN103889419A (zh) 2011-10-28 2014-06-25 默沙东公司 在电压门控钠离子通道中具有选择性活性的苯并噁唑啉酮化合物
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
PE20150400A1 (es) * 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
US9376429B2 (en) 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
BR112015008987A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
AU2013334663A1 (en) 2012-10-26 2015-05-07 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
CN105705501B (zh) 2013-09-09 2019-04-19 百时美施贵宝公司 RORγ调节剂
US20160221974A1 (en) 2013-09-10 2016-08-04 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CN105793238B (zh) * 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
CA2934473C (en) 2013-12-23 2019-08-20 Purdue Pharma L.P. Indazoles and use thereof
EP3166939B1 (en) * 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
BR112018012408A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica?
EP3458449B1 (en) 2016-05-20 2025-03-05 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
AU2017371674B2 (en) 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
UA127024C2 (uk) * 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques

Similar Documents

Publication Publication Date Title
JP2019516737A5 (enExample)
RU2018145045A (ru) Соединения бензолсульфонамида и их применение в качестве терапевтических средств
JP2010533158A5 (enExample)
JP5261383B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
RU2005106844A (ru) [1,2,4]оксодиазолы (варианты), способ их получения, и фармацевтическая композиция и способ (варианты) ингибирования активации метаботропных глютаматных рецепторов-5
JP2006503009A5 (enExample)
JP2015517580A5 (enExample)
JP2004502670A5 (enExample)
JP2021500345A5 (enExample)
JP2018535999A5 (enExample)
JP2020530446A5 (enExample)
JP2009542659A5 (enExample)
JP2007528887A5 (enExample)
JP2020516671A5 (enExample)
JP2005504058A5 (enExample)
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
JP2006506340A5 (enExample)
JP2009525340A5 (enExample)
JP2007523208A5 (enExample)
JP2013533868A5 (enExample)
JP2006524686A5 (enExample)
JP2010540462A5 (enExample)
JP2018507234A5 (enExample)
RU2019117556A (ru) Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
JP2011500679A5 (enExample)